22/08/2024 - General information
The Council for International Organizations of Medical Sciences, an entity created by the World Health Organization and UNESCO to help advance public health through guidance on research and health policies, has published the report Real-world data and real-world evidence in regulatory decision', in which Dr. Miguel Ángel Mayer, from the Management Control department of Hospital del Mar and its research institute, has participated. The report aims to provide a universal consensus document that can be used to facilitate the harmonization of regulatory standards and definitions, articulate the requirements to support the determination of drug efficacy, and help develop a set of ethical guidelines for real-world data (RWD) and real-world evidence (RWE) by expanding the use of RWD/RWE for decision-making throughout the entire lifecycle of medical products.
10/07/2024 - Press release
A study published in Science Advances identifies a set of microproteins that are exclusively produced in liver tumors. This makes them a clear target for immune system cells and a potential target for cancer vaccine development. The research was led by the Evolutionary Genomics Research Group at the Hospital del Mar Research Institute, in collaboration with Cima University of Navarra and Pompeu Fabra University. Various state-of-the-art tools were used to detect and identify these small molecules in samples from over a hundred tumors.
Més informació "Microproteins Found in Tumors Could Lead to Cancer Vaccines"
29/06/2023 - General information
The project, jointly coordinated by UPF professor Ferran Sanz, has enjoyed the participation of numerous members of the GRIB; the UPF research programme in Medical Bioinformatics and the Hospital del Mar Research Institute, as well as the spinoff Med Bioinformatics Solutions, which emerged from the same programme. eTRANSAFE, the European project to share data on the safety of medicines, has come to fruition. On a single platform, the project has integrated data from more than 10,000 pharmacological studies by reference pharmaceutical companies, from a dozen databases that amass public and private information of clinical and preclinical studies. The project has also developed 'Flame', an open-source machine learning application that allows predicting whether future drugs will have adverse effects.
Més informació "Culmination of the eTRANSAFE project to share data on the safety of medicines"
24/02/2023 - Institutional news
It is led by Dr. Mario Cáceres, ICREA researcher who joins IMIM-Hospital del Mar in its talent attraction program. The group focuses on the application of the latest techniques in the field of genomics to analyze the relationship between changes in the genome and various fields of health. Dr. Mario Cáceres joins IMIM-Hospital del Mar heading a new research group, the Comparative and Functional Genomics Research Group. The arrival of Dr. Cáceres Aguilar, ICREA researcher, has come about thanks to the talent attraction program launched at the institution to boost the research carried out with top-level researchers.
22/12/2022 - Institutional news
The European Medicines Agency selected Hospital del Mar Medical Research Institute and the Hospital del Mar to be a Data Partner of the DARWIN EU® data network, an EU-wide federated network of high-quality observational healthcare databases across Europe, that provides expertise and services to support regulatory decision-making throughout the lifecycle of medicinal products. The Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) is one of the first eight European centres currently selected to participate in the European Union's DARWIN EU® initiative to carry out multicentre observational studies on medicines. The data available to these partners will be used for studies to generate real-world evidence that will support scientific evaluations and regulatory decision making.
04/05/2022 - Press release
The Biomedical Informatics Research Programme of IMIM-Hospital del Mar has received one of the European Research Council (ERC) grants for the NovoGenePop project, the ERC Advanced Grant. Among the 253 researchers selected, only thirteen are from Spain. The project at the IMIM-Hospital del Mar, the only Spanish biomedical research centre to be selected, will develop bioinformatics tools to identify specific genes in certain individuals or populations. This may pave the way for accelerated research in fields such as cancer and hereditary diseases. In total, the ERC Advanced Grants have distributed 624 million between 253 European researchers. This is the fourth grant of this type that the IMIM-Hospital del Mar has received in the last years.
23/03/2022 - General information
The European Research Network on Signal Transduction (ERNEST), of which IMIM is a member, has created an Emergency Fund for Ukrainian researchers. Researchers affiliated to any legal entity in Ukraine (for example, schools and universities, research centers, governmental institutions, or private companies) are eligible to apply for this funding. For more information you can contact Jana Selent (vice-chair of the ERNEST - Cost Action 18133) or visit this website
18/01/2022 - General information
The predoctoral researcher Lilian Boll from the Evolutionary Genomics Research Group of the GRIB (IMIM-UPF) has obtained one of the 65 grants of the INPhINIT PhD Program of La Caixa Foundation for her project "Identification of neo-epitopes in cancer derived from non-canonical proteins and their potential use in immunotherapy" to study neoantigens. Neoantigens are tumor-specific antigens generated by mutations in tumor cells, which are only expressed in tumor cells. "One of the approaches in immunotherapy is to block cellular checkpoints so that the immune system recognizes tumor cells by their neoantigens," explains Lilian Boll.
14/12/2021 - Press release
This new resource, developed by the GPCR Drug Discovery Group at the Hospital del Mar Medical Research Institute, provides a three-dimensional analysis of the movements of COVID-19 proteins. This can help researchers understand how they work and develop new treatments and vaccines The tool, available online to all researchers, offers a large number of simulations of how these proteins work, as well as resources for predicting how their function could change in relation to mutations that may occur in the structure of this coronavirus The scientists behind the initiative used more than 360 gigabits of data to develop it. To date, it is the only database for studying SARS-CoV-2 that combines protein simulations with mutation data
09/09/2021 - General information
A study lead by researchers from the Hospital del Mar Medical Research Institute (IMIM) and the Centre for Cellular and Molecular Biology of the Council Of Scientific And Industrial Research (CSIR) published in the Science Advances journal, shows for the first time how cholesterol can interfere with the function of a important receptor present in brain cells - the serotonin receptor. This finding is of great importance, as it allows to devise new ways to modulate those receptors, which in the future could lead to the development of new drugs to treat diseases of the central nervous system. Cholesterol is an essential component of the neuron membrane. Multiple proteins reside within those membranes, including GPCRs (G-protein coupled receptors). GPCRs are a large receptor family, encompassing serotonin receptors, which act as cellular receptors, detecting outside signals and transmitting towards the cell. Because of this, GPCRs are crucial for correct communications between cells.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
